We are live on ! Find out more
KAM

Krensavage Asset Management Portfolio holdings

AUM $256M
1-Year Est. Return 69.63%
This Fund
S&P 500
This Quarter Est. Return
+1.96%
1 Year Est. Return
+69.63%
3 Year Est. Return
+113.28%
5 Year Est. Return
+196.5%
10 Year Est. Return
+463.27%
AUM
$329M
AUM Growth
+$5.63M
Cap. Flow
+$5.04M
Cap. Flow %
1.53%
Top 10 Hldgs %
98.39%
Holding
12
New
–
Increased
6
Reduced
6
Closed
–

Top Buys

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$2.48M
2
CAH icon
Cardinal Health
CAH
+$1.55M
3
EMBC icon
Embecta
EMBC
+$1.26M
4
ENTA icon
Enanta Pharmaceuticals
ENTA
+$405K
5
VNDA icon
Vanda Pharmaceuticals
VNDA
+$114K

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$464K
2
ALKS icon
Alkermes
ALKS
+$163K
3
TARO
Taro Pharmaceutical Industries Ltd.
TARO
+$80.3K
4
EXEL icon
Exelixis
EXEL
+$37.8K
5
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$32.3K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIIB icon
1
Biogen
BIIB
$30B
$49.2M 14.96%
177,126
+122
+0.1% +$33.8K
REGN icon
2
Regeneron Pharmaceuticals
REGN
$78.5B
$48.9M 14.84%
59,488
-615
-1% -$464K
UTHR icon
3
United Therapeutics
UTHR
$25.8B
$45.3M 13.75%
202,110
+10,062
+5% +$2.48M
EXEL icon
4
Exelixis
EXEL
$13.3B
$41.5M 12.59%
2,135,868
-2,171
-0.1% -$37.8K
ALKS icon
5
Alkermes
ALKS
$8.22B
$39.3M 11.95%
1,395,797
-5,986
-0.4% -$163K
EMBC icon
6
Embecta
EMBC
$216M
$29.9M 9.07%
1,062,123
+44,466
+4% +$1.26M
CAH icon
7
Cardinal Health
CAH
$53.9B
$26.7M 8.1%
353,278
+20,529
+6% +$1.55M
ENTA icon
8
Enanta Pharmaceuticals
ENTA
$366M
$24.4M 7.41%
603,301
+8,483
+1% +$405K
TARO
9
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$15.6M 4.74%
641,910
-2,754
-0.4% -$80.3K
EGRX
10
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$3.23M 0.98%
113,737
-1,088
-0.9% -$32.3K
KOD icon
11
Kodiak Sciences
KOD
$2.6B
$2.85M 0.87%
459,489
-4,109
-0.9% -$28.8K
VNDA icon
12
Vanda Pharmaceuticals
VNDA
$307M
$2.46M 0.75%
361,560
+16,270
+5% +$114K

Similar funds

CIA
Corigliano Investment Advisers Raleigh, North Carolina $256M AUM 54.89% 1-Year Est. Return
2
2Xideas Kusnacht, Switzerland $255M AUM 0.46% 1-Year Est. Return
CIM
Caldwell Investment Management Toronto, Ontario, Canada $255M AUM 36.87% 1-Year Est. Return
JFG
Juno Financial Group Richmond, Virginia $255M AUM
PIP
Palisades Investment Partners Santa Monica, California $255M AUM 50.52% 1-Year Est. Return
LRIC
Long Road Investment Counsel Kalamazoo, Michigan $255M AUM 12.85% 1-Year Est. Return
GAMC
Garner Asset Management Corp Plano, Texas $255M AUM 22.93% 1-Year Est. Return
TIA
Tiemann Investment Advisors Menlo Park, California $255M AUM 21.35% 1-Year Est. Return

Krensavage Asset Management's Q1 2023 Portfolio in Review

As of Q1 2023, Krensavage Asset Management held 12 positions worth $329M, up 1.7% from $324M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Trading was light in Q1 2023: portfolio turnover was 0%. Krensavage Asset Management opened no new positions and made no exits, leaving the 12-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Krensavage Asset Management added most to United Therapeutics in Q1 2023, an estimated $2.48M increase.
  • Krensavage Asset Management's biggest Q1 2023 reduction was Regeneron Pharmaceuticals, cutting an estimated $464K.
  • Krensavage Asset Management's ten largest holdings make up 98% of its $329M portfolio in Q1 2023.
  • Krensavage Asset Management opened 0 new positions and closed 0 in Q1 2023.
  • Krensavage Asset Management's portfolio value rose 1.7% quarter-over-quarter to $329M.

Based on Krensavage Asset Management's 13F filing for Q1 2023, filed 16 May 2023.